NO20004306L - Farmasøytiske sammensetninger som inneholder fosfolipaseinhibitoren natrium[[3-(2-amino-1,2-dioksoetyl-1- fenylmetyl)-1H-indol-4-yl]oksy)acetat - Google Patents

Farmasøytiske sammensetninger som inneholder fosfolipaseinhibitoren natrium[[3-(2-amino-1,2-dioksoetyl-1- fenylmetyl)-1H-indol-4-yl]oksy)acetat

Info

Publication number
NO20004306L
NO20004306L NO20004306A NO20004306A NO20004306L NO 20004306 L NO20004306 L NO 20004306L NO 20004306 A NO20004306 A NO 20004306A NO 20004306 A NO20004306 A NO 20004306A NO 20004306 L NO20004306 L NO 20004306L
Authority
NO
Norway
Prior art keywords
dioxoethyl
phenylmethyl
indol
oxy
acetate
Prior art date
Application number
NO20004306A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004306D0 (no
Inventor
William Lester Confer
Hideaki Tai
Original Assignee
Shionogi & Co
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co, Lilly Co Eli filed Critical Shionogi & Co
Publication of NO20004306D0 publication Critical patent/NO20004306D0/no
Publication of NO20004306L publication Critical patent/NO20004306L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20004306A 1998-03-03 2000-08-29 Farmasøytiske sammensetninger som inneholder fosfolipaseinhibitoren natrium[[3-(2-amino-1,2-dioksoetyl-1- fenylmetyl)-1H-indol-4-yl]oksy)acetat NO20004306L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7665998P 1998-03-03 1998-03-03
PCT/US1999/004516 WO1999044604A1 (en) 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate

Publications (2)

Publication Number Publication Date
NO20004306D0 NO20004306D0 (no) 2000-08-29
NO20004306L true NO20004306L (no) 2000-10-10

Family

ID=22133426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004306A NO20004306L (no) 1998-03-03 2000-08-29 Farmasøytiske sammensetninger som inneholder fosfolipaseinhibitoren natrium[[3-(2-amino-1,2-dioksoetyl-1- fenylmetyl)-1H-indol-4-yl]oksy)acetat

Country Status (21)

Country Link
US (1) US6166062A (zh)
EP (1) EP1058547B1 (zh)
JP (3) JP2002505282A (zh)
KR (1) KR20010034552A (zh)
CN (1) CN1299277A (zh)
AT (1) ATE310513T1 (zh)
AU (1) AU757002B2 (zh)
BR (1) BR9908479A (zh)
CA (1) CA2322796A1 (zh)
DE (1) DE69928500T2 (zh)
EA (1) EA003864B1 (zh)
ES (1) ES2253877T3 (zh)
HU (1) HUP0102812A3 (zh)
ID (1) ID27487A (zh)
IL (1) IL138154A0 (zh)
NO (1) NO20004306L (zh)
NZ (1) NZ506578A (zh)
PL (1) PL342822A1 (zh)
TR (1) TR200002543T2 (zh)
TW (1) TW570795B (zh)
WO (1) WO1999044604A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236440A1 (en) * 2000-01-25 2001-08-07 Eli Lilly And Company Method for the treatment of inflammation with spla2 inhibitors
JP2003525901A (ja) * 2000-03-09 2003-09-02 イーライ・リリー・アンド・カンパニー sPLA2インヒビターによる腎臓機能障害の治療方法
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
CN1568999A (zh) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
EP1742535A4 (en) * 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN
PT2029134E (pt) * 2006-06-09 2011-11-02 Ucb Pharma Gmbh Composições farmacêuticas estabilizadas compreendendo fesoterodina
WO2008100235A2 (fr) * 2007-02-12 2008-08-21 Medis Lab Le sucralose solution sterile sans conservateurs
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20140053952A (ko) * 2011-08-26 2014-05-08 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
EP2923710A1 (en) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
JPH02207092A (ja) * 1989-02-07 1990-08-16 Kirin Brewery Co Ltd アンスラサイクリン化合物またはその塩の凍結乾燥製剤の製造法
ES2142409T3 (es) * 1993-10-27 2000-04-16 Upjohn Co Prostaglandina e 1 estabilizada.
KR100368707B1 (ko) * 1994-04-01 2003-06-02 일라이 릴리 앤드 캄파니 1H-인돌-3-글리옥실아미드sPLA2억제제

Also Published As

Publication number Publication date
DE69928500D1 (de) 2005-12-29
NZ506578A (en) 2003-09-26
ES2253877T3 (es) 2006-06-01
JP2006096761A (ja) 2006-04-13
ID27487A (id) 2001-04-12
US6166062A (en) 2000-12-26
PL342822A1 (en) 2001-07-02
CN1299277A (zh) 2001-06-13
BR9908479A (pt) 2000-12-05
AU757002B2 (en) 2003-01-30
ATE310513T1 (de) 2005-12-15
WO1999044604A9 (en) 2000-01-20
EA200000897A1 (ru) 2001-02-26
HUP0102812A3 (en) 2002-01-28
JP2011021042A (ja) 2011-02-03
CA2322796A1 (en) 1999-09-10
AU2799899A (en) 1999-09-20
EP1058547B1 (en) 2005-11-23
TR200002543T2 (tr) 2000-11-21
WO1999044604A1 (en) 1999-09-10
JP2002505282A (ja) 2002-02-19
EP1058547A1 (en) 2000-12-13
IL138154A0 (en) 2001-10-31
DE69928500T2 (de) 2006-08-03
NO20004306D0 (no) 2000-08-29
TW570795B (en) 2004-01-11
HUP0102812A2 (hu) 2001-12-28
EA003864B1 (ru) 2003-10-30
KR20010034552A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
NO20004306L (no) Farmasøytiske sammensetninger som inneholder fosfolipaseinhibitoren natrium[[3-(2-amino-1,2-dioksoetyl-1- fenylmetyl)-1H-indol-4-yl]oksy)acetat
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
BRPI0500968A (pt) Emulsificador
DE69940354D1 (de) Adenovirus-formulierungen zur gentherapie
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
AR077412A2 (es) Formulacion farmaceutica composicon farmaceutica acuosa y formulacion farmaceutica acuosa liquida que comprende un anticuerpo
UY27320A1 (es) Nuevas composiciones farmacéuticas
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
HUP0300850A2 (hu) Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
DE602004015725D1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
TR199802394A2 (xx) Proteinleri stabilize etmek i�in geli�tirilmi� proses.
BR0111678A (pt) Composições medicinais contendo derivados de propenona
AR006523A1 (es) Compuestos ciclicos, inhibidores de la adhesion
AR044864A1 (es) Composiciones orales antiplaca acuosas estables
ATE302587T1 (de) Gebissreinigungsmittel
PT769951E (pt) Composicao de oxitetraciclina de longa accao
BR0009214A (pt) Composições aquosas estáveis contendo umcomposto de silìcio
ATE254457T1 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application